on SARTORIUS AG (isin : DE0007165631)
Sartorius Reports Strong Growth and Positive Outlook for 2026
Göttingen-based Sartorius AG has announced its preliminary results for 2025, revealing a significant increase in sales revenue by 7.6% to approximately €3.5 billion. Both its divisions, Bioprocess Solutions and Lab Products & Services, contributed positively. The Bioprocess Solutions division led with a growth of 9.5% in constant currencies, driven by sustained demand in consumables.
The company reported an increase in its underlying EBITDA margin to 29.7%, reflecting efficient cost management and economies of scale. The total investments in research and production infrastructure expanded to €442 million, strengthening its global footprint.
Looking ahead to 2026, Sartorius anticipates continued profitable growth, projecting sales revenue growth between 5% and 9%. CEO Dr. Michael Grosse expressed confidence in maintaining the growth trajectory despite macroeconomic uncertainties, reiterating the company's focus on innovation and customer support.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SARTORIUS AG news